Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions.
Rashedi S, Leyva H, Hamade N, Pfeferman MB, Ortega-Paz L, Sadeghipour P, Talasaz AH, O'Donoghue ML, Jimenez D, Monreal M, Anderson CD, Elkind MSV, Lang IM, Weitz JI, Goldhaber SZ, De Caterina R, Konstantinides SV, Piazza G, Krumholz HM, Braunwald E, Bikdeli B.
Rashedi S, et al.
J Am Coll Cardiol. 2025 Oct 7;86(14):1065-1087. doi: 10.1016/j.jacc.2025.07.061.
J Am Coll Cardiol. 2025.
PMID: 41033744
Review.
Although fibrinolytic therapy in patients with ST-segment elevation myocardial infarction is currently restricted to those who cannot undergo primary percutaneous coronary intervention within 120 minutes of presentation, it has been a mainstay treatment for acute ischemic stroke …
Although fibrinolytic therapy in patients with ST-segment elevation myocardial infarction is currently restricted to those who cannot underg …